JP2019528693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528693A5 JP2019528693A5 JP2019510849A JP2019510849A JP2019528693A5 JP 2019528693 A5 JP2019528693 A5 JP 2019528693A5 JP 2019510849 A JP2019510849 A JP 2019510849A JP 2019510849 A JP2019510849 A JP 2019510849A JP 2019528693 A5 JP2019528693 A5 JP 2019528693A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- amino acid
- peptide
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 34
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 229940122985 Peptide agonist Drugs 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 claims 5
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 5
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 241000283070 Equus zebra Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000000763 Survivin Human genes 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 1
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 claims 1
- 101000801539 Homo sapiens Mitochondrial import receptor subunit TOM34 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100033583 Mitochondrial import receptor subunit TOM34 Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2016/072475 | 2016-09-21 | ||
| EP2016072475 | 2016-09-21 | ||
| PCT/EP2017/073954 WO2018055060A1 (en) | 2016-09-21 | 2017-09-21 | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528693A JP2019528693A (ja) | 2019-10-17 |
| JP2019528693A5 true JP2019528693A5 (enExample) | 2020-11-05 |
| JP7346291B2 JP7346291B2 (ja) | 2023-09-19 |
Family
ID=60037562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510849A Active JP7346291B2 (ja) | 2016-09-21 | 2017-09-21 | 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190255165A1 (enExample) |
| EP (1) | EP3515476B1 (enExample) |
| JP (1) | JP7346291B2 (enExample) |
| KR (2) | KR20190057345A (enExample) |
| CN (1) | CN109963585B (enExample) |
| AU (1) | AU2017331949B2 (enExample) |
| CA (1) | CA3031170A1 (enExample) |
| CL (3) | CL2019000694A1 (enExample) |
| DK (1) | DK3515476T3 (enExample) |
| ES (1) | ES2983085T3 (enExample) |
| HU (1) | HUE067838T2 (enExample) |
| IL (1) | IL265479B (enExample) |
| MX (1) | MX2019002968A (enExample) |
| PL (1) | PL3515476T3 (enExample) |
| WO (1) | WO2018055060A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| RU2769314C1 (ru) | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| HUE067838T2 (hu) * | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| BR112019020853A2 (pt) | 2017-04-04 | 2020-05-12 | Avidea Technologies, Inc. | Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune |
| US12121573B2 (en) | 2019-07-14 | 2024-10-22 | Tianxin Wang | Methods and agents including STING agonist to treat tumor |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| CA3141084A1 (en) * | 2019-06-12 | 2020-12-17 | Vikram JUNEJA | Neoantigen compositions and uses thereof |
| CN110448689A (zh) * | 2019-08-06 | 2019-11-15 | 太仓美诺恒康生物技术有限公司 | mRNA疫苗及其试剂盒、应用 |
| WO2021102215A1 (en) * | 2019-11-22 | 2021-05-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for increasing transduction efficiency with cell membrane fusion proteins |
| EP3827840A1 (en) * | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| MX2023002884A (es) * | 2020-09-14 | 2023-03-31 | Boehringer Ingelheim Int | Vacuna heterologa de estimulo primario. |
| WO2022079175A1 (en) * | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
| CN113480666B (zh) * | 2021-08-13 | 2024-01-26 | 郑州伊美诺生物技术有限公司 | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 |
| CN113786481A (zh) * | 2021-09-27 | 2021-12-14 | 深圳市中佳生物医疗科技有限公司 | 一种抗肿瘤疫苗及其制备方法 |
| MX2024011238A (es) * | 2022-03-16 | 2024-09-19 | Boehringer Ingelheim Int | Antigenos tumorales, compuestos que comprenden los antigenos tumorales kras, tpx2 o aurka y usos de los mismos. |
| KR102823824B1 (ko) | 2022-08-10 | 2025-06-24 | 강원대학교산학협력단 | Pde5 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도 |
| KR102886457B1 (ko) | 2022-10-14 | 2025-11-18 | 강원대학교산학협력단 | mTOR 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도 |
| GB202216453D0 (en) * | 2022-11-04 | 2022-12-21 | Lisziewicz Julianna | Identification of antigens which induce t-cell responses |
| WO2024196664A1 (en) * | 2023-03-17 | 2024-09-26 | University Of Washington | Dna vaccine targeting overexpressed antigens in colorectal cancer |
| JP7723457B2 (ja) * | 2023-07-03 | 2025-08-14 | メスキュージェナシス株式会社 | 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| PL209127B1 (pl) * | 2000-02-23 | 2011-07-29 | Smithkline Beecham Biolog | Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| GB0218821D0 (en) | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| JP2007519612A (ja) | 2003-10-15 | 2007-07-19 | イスティチュート スペリオーレ ディ サニータ | 結腸直腸癌抗原 |
| US20080305120A1 (en) | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| AU2006209951B2 (en) | 2005-02-04 | 2011-04-14 | Survac Aps | Survivin peptide vaccine |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| NZ720288A (en) | 2006-12-27 | 2020-02-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| BRPI0813621A2 (pt) | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| MX2010001194A (es) | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009130618A2 (en) | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| EP2303319B1 (en) | 2008-06-20 | 2016-10-05 | Duke University | Compositions, methods and kits for eliciting an immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101040281B1 (ko) * | 2008-08-22 | 2011-06-10 | 가톨릭대학교 산학협력단 | Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
| US8074880B2 (en) | 2008-12-01 | 2011-12-13 | Research In Motion Limited | Method, system and mobile device employing enhanced fingerprint authentication |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2755790A1 (en) | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| BRPI1012078A2 (pt) * | 2009-05-27 | 2019-09-24 | Glaxosmithkline Biologicals Sa | construto de proteína, composição imunogênica, molécula de ácido nucleico , métodos de induzir uma resposta imune a casb7439 e de tratar um animal humano ou não-humano, e, uso de uma composição imunogênica |
| EP2459594A1 (en) | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| US20120237535A1 (en) | 2009-09-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Therapeutic Compositions For The Treatment of HPV-Induced Diseases |
| EP2480568B1 (en) | 2009-09-23 | 2016-04-20 | Université Paris Descartes | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011135222A2 (fr) | 2010-04-26 | 2011-11-03 | Universite Joseph Fourier | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| EP4159226A1 (en) | 2010-08-24 | 2023-04-05 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| AU2011303430B2 (en) | 2010-09-14 | 2014-09-11 | Council Of Scientific And Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
| WO2012048190A1 (en) | 2010-10-08 | 2012-04-12 | Regents Of The University Of Minnesota | Annexin ii compositions and methods |
| KR101760464B1 (ko) | 2010-10-13 | 2017-07-24 | 사회복지법인 삼성생명공익재단 | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 |
| SG191830A1 (en) | 2011-01-10 | 2013-08-30 | Cleveland Biolabs Inc | Use of toll-like receptor agonist for treating cancer |
| US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| US8795678B2 (en) | 2011-05-13 | 2014-08-05 | Academia Sinica | TLR-2 agonists and methods of use thereof |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| PE20141937A1 (es) | 2011-11-16 | 2014-12-18 | Amgen Inc | Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| US9597393B2 (en) | 2012-02-09 | 2017-03-21 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (TLR-4) agonist peptides |
| AU2013289372B2 (en) * | 2012-07-13 | 2017-11-02 | S-Target Therapeutics Gmbh | Immunoregulatory vaccine |
| JP6306593B2 (ja) | 2012-09-13 | 2018-04-04 | ユニベルシテ ドゥ ジュネーブ | 細胞透過性ペプチド |
| BR112015006176B1 (pt) | 2012-09-21 | 2023-04-18 | Intensity Therapeutics, Inc | Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular |
| WO2014070663A1 (en) | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| EP2968407A4 (en) | 2013-03-13 | 2017-01-04 | Neostem Oncology, LLC | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| CN106061981A (zh) | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| HUE060293T2 (hu) * | 2013-11-13 | 2023-02-28 | Univ Minnesota | Annexin II variáns készítmények és eljárások |
| KR20160102314A (ko) | 2014-01-02 | 2016-08-29 | 메모리얼 슬로안-케터링 캔서 센터 | 면역 치료요법에 대한 암 반응의 결정인자 |
| EP3152308A4 (en) | 2014-06-06 | 2017-12-27 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| JP7523203B2 (ja) * | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| CA2966660A1 (en) * | 2014-11-13 | 2016-05-19 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| WO2017002345A1 (ja) | 2015-06-29 | 2017-01-05 | パナソニックＩｐマネジメント株式会社 | 冷蔵庫 |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| DK3400290T5 (da) | 2016-01-08 | 2024-09-23 | Replimune Ltd | Onkolytisk virusstamme |
| WO2017120670A1 (en) | 2016-01-11 | 2017-07-20 | Brian Lichty | Oncolytic virus and checkpoint inhibitor combination therapy |
| RU2769314C1 (ru) | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| CN109415705A (zh) | 2016-05-09 | 2019-03-01 | 图恩斯通有限合伙公司 | 组合初免:加强免疫疗法 |
| PL417980A1 (pl) | 2016-07-16 | 2018-01-29 | Univ Warszawski | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| WO2018053508A1 (en) | 2016-09-19 | 2018-03-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| JP7457642B2 (ja) | 2017-04-03 | 2024-03-28 | ビオンテック ユーエス インコーポレイテッド | タンパク質抗原およびその使用 |
| WO2019150310A1 (en) | 2018-02-02 | 2019-08-08 | Novartis Ag | Combination of sting agonist and il-15/il15-ra for the treatment of cancer |
| EP3810151B1 (en) | 2018-06-20 | 2025-08-06 | Yale University | Rig-i agonists and treatments using same |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| MX2023002884A (es) | 2020-09-14 | 2023-03-31 | Boehringer Ingelheim Int | Vacuna heterologa de estimulo primario. |
| WO2022079175A1 (en) * | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
-
2017
- 2017-09-21 HU HUE17780656A patent/HUE067838T2/hu unknown
- 2017-09-21 JP JP2019510849A patent/JP7346291B2/ja active Active
- 2017-09-21 US US16/331,398 patent/US20190255165A1/en not_active Abandoned
- 2017-09-21 AU AU2017331949A patent/AU2017331949B2/en active Active
- 2017-09-21 MX MX2019002968A patent/MX2019002968A/es unknown
- 2017-09-21 IL IL265479A patent/IL265479B/en unknown
- 2017-09-21 EP EP17780656.9A patent/EP3515476B1/en active Active
- 2017-09-21 KR KR1020197011382A patent/KR20190057345A/ko not_active Ceased
- 2017-09-21 WO PCT/EP2017/073954 patent/WO2018055060A1/en not_active Ceased
- 2017-09-21 CN CN201780069631.0A patent/CN109963585B/zh active Active
- 2017-09-21 CA CA3031170A patent/CA3031170A1/en active Pending
- 2017-09-21 ES ES17780656T patent/ES2983085T3/es active Active
- 2017-09-21 KR KR1020237029678A patent/KR102879364B1/ko active Active
- 2017-09-21 PL PL17780656.9T patent/PL3515476T3/pl unknown
- 2017-09-21 DK DK17780656.9T patent/DK3515476T3/da active
-
2019
- 2019-03-18 CL CL2019000694A patent/CL2019000694A1/es unknown
-
2020
- 2020-11-25 US US17/104,786 patent/US11338027B2/en active Active
-
2021
- 2021-06-11 CL CL2021001541A patent/CL2021001541A1/es unknown
-
2022
- 2022-04-12 US US17/718,975 patent/US12220387B2/en active Active
-
2023
- 2023-07-31 CL CL2023002252A patent/CL2023002252A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528693A5 (enExample) | ||
| JP2018509936A5 (enExample) | ||
| JP2018510215A5 (enExample) | ||
| AU2020201896B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| AU2016368433B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| AU2022268324B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| HRP20200491T1 (hr) | Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma | |
| AR121588A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| TW201841934A (zh) | 用於治療癌症免疫治療的新穎肽及其肽組合物 | |
| PE20240778A1 (es) | Nuevos peptidos y combinacion de peptidos para usar en inmuterapia contra el cancer esofagico y otros canceres | |
| AU2022204032B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| CN111533796A (zh) | 用于癌症免疫治疗的肽及其肽组合物 | |
| US20250312428A1 (en) | Heterologous Prime Boost Vaccine | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| PH12013501105A1 (en) | Tomm34 peptides and vaccines including the same | |
| MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
| V. Savvateeva et al. | Prophylactic admission of an in vitro reconstructed complexes of human recombinant heat shock proteins and melanoma antigenic peptides activates anti-melanoma responses in mice | |
| JP2013540419A5 (enExample) | ||
| JP2010530748A5 (enExample) | ||
| JP2017500305A5 (enExample) | ||
| CN108929867B (zh) | 抗肿瘤的多肽及其制备方法和应用 | |
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination | |
| Li | Role of heat shock protein in chaperoning tumor antigens and modulating anti-tumor immunity |